Mendoza-Olivas LG, Santana-de Anda K, Medina-López Z, Estañol-Vidal B

Language: Spanish
References: 16
Page: 23-30
PDF size: 244.15 Kb.

ABSTRACT

Introduction: The primary Sjögren syndrome (PSS) implies a number of extraglandular manifestations, the prevalence of neurological manifestations is variable. Previous studies suggest that anti-SSA and anti-SSB are associated with involvement of the CNS, but those results are controversial.
Objective: To test whether a difference exists in levels of anti-SSA and anti-SSB in PSS with or without extraglandular manifestations.
Methods: This is a retrospective cohort study. We examined the clinical value of anti-SSA and anti- SSB in 182 patients at the time of PSS diagnosis. We documented if they developed a neurological manifestation attributable to PSS. We then compared the level of antibodies between patients with and without neurological manifestations developed during clinical evolution.
Results: We included 182 patients, 94.5% women, aged 60 ± 15.3 years. We found 48 patients (26.3%) with a neurological complication, the most common was axonal distal sensory-motor polyneuropathy and only three patients had CNS implication. There were no differences in the level of antibodies in patients with and without neurological manifestations. We found that anti- SSB levels were significantly higher in patients with other type of extraglandular manifestations (p=0.03).
Conclusions: We found no difference in antibodies levels between patients with or without neurological complications, attributable in part to the low prevalence of neurological manifestations and the retrospective nature of our work. Our observations form the basis for studying the role of antibodies in the genesis of the extraglandular manifestations of SSP in our population. Ethnicity may play an important role.

REFERENCES

1. Tzioufas AG, Voulgarelis M. Update on Sjögren s syndrome autoimmune epithelitis: from ́ classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007;21:989¬1010.

2. Josiah Chai, Eric L. Logigian. Neurological manifestations of primary Sjögren s syndrome. Current ́ Opinion in Neurology 2010;23:509-513.

3. Andonopoulos AP, Lagos G, Drosos AA, Moutsopoulos HM. Neurologic involvement in primary Sjögren s syndrome: a preliminary report. JAutoimmun 1989;2:485¬5.

4. Ramos¬Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino Montes J, GEMESS StudyGroup, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008;87:210¬19.

5. C Vitali et al. Classification criteria for Sjögren s syndrome: a revised version of the European ́ criteria proposed by the American -European Consensus Group. Ann Rheum Dis 2002,61:554¬558.

6. Ren H, Wang WM, Chen XN, Zhang W et al. Renal involvement and follow up of 130 patientes with primary Sjögren ́s syndrome. J Rheumatol 2008 Feb;35 (2):278¬84.

7. Jara LJ, Navarro C, Brito ZerónMdel P, et al. Thyroid disease in Sjögren ́s syndrome. Clinical Rheumatology 2007;26(10):1601¬6.

8. Bernacchi E, Amato L, Paroid A, et al. Sjögren ́s syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clinical and ExpRheumatol 2004;22(1):55.

9. P.P. Pavlakis, H. Alexopoulos, M.L. Kosmidis, I. Mamali, H.M. Moutsopoulos, A.G. Tzioufas, M.C. Dalakas. Peripheral neuropathies in Sjögren s syndrome: A critical update on clinical features and ́ pathogenetic mechanisms.

10. Sophie Delalande, et al. Neurologic Manifestations in Primary Sjögren ́s syndrome: A study of 82 patients. Medicine 2004;83:280¬291.

11. P.P Pavlakis et al. Peripheral neuropathies in Sjögren s syndrome: a new reappraisal. J ́ NeurolNeurosurg Psychiatry 2011;82:798¬802.

12. Tezcan ME, Kocer EB, Haznedaroglu S, Sonmez C, Mercan R, Yucel AA, Irkec C et al. Primary Sjögren’s Syndrome is associated with significant cognitive disfunction. International Journal of Rheumatic Diseases

13. Laure M, Toulgoat F, Desal H, Magot A, Hamidou M. Atypical Neurologic complications in Patients with Primary Sjögren Syndrome. Semin Arthritis Rheum Vol. 40 Issue 4 p338-342.

14. Lin Q, Wang Q, Yunyun F, Zhang W, Xu Y, Zhang Y et al. The Clinical Characteristics of primary Sjögren’s Syndrome with Neuromyelitis Optica Spectrum Disorder in China. Medicine 94(28):e1145.

15. Andonopoulos AP, Lagos G, Drosos AA, Moutospoulos HM. The spectrum of neurological involvement in Sjögren ́s syndrome. Br J Rheumatol 1990;29:21¬3.

16. Wingerchuk D. Diagnosis and Treatment of Neuromyelitis Optica. The Neurologist 2007;13:2-11.